An interventional study of Dry electrode EEG in Ischemic Stroke, Stroke and Cardiovascular Diseases, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Ischemic Stroke with a site in Netherlands — 14 open to participants now, 17 under way, 2 of them phase 3. Ischemic Stroke · Netherlands.
Among the 45 studies in Ischemic Stroke with a site in Netherlands, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 40th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →14 of the 45 studies in Ischemic Stroke with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Isala · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Netherlands, Austria, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 275 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 447 across the 34 interventional studies, 300 across the 11 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 45 have an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 7 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06871969Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance | 2026-12 |
| NCT05853796Radboud University Medical CenterObservational Dutch Young Symptomatic StrokE studY - nEXT | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Ischemic Stroke with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.
To address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.
RATIONALE Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) stroke. However, EVT can only be performed in specialized hospitals and its effect on functional outcome rapidly decreases with passing time (time = brain). Since ambulance personnel cannot determine whether a patient has a stroke that is eligible for EVT, 54% of patients with an LVO stroke are primarily presented at a non-EVT capable hospital. These patients then require interhospital transfer, resulting in average delay in time-to-EVT of 1 hour in the Netherlands. Therefore, providing ambulance personnel with tools to identify patients with a possible LVO stroke in the ambulance, allowing direct transport to an EVT capable hospital, is much needed. Dry electrode electroencephalography (EEG) has shown to have a high diagnostic accuracy for LVO stroke detection among patients with a suspected stroke (area under the receiving operating curve [AUC]: 0.91). However, in 32% of patients EEG signal quality was too poor to analyse. A new portable EEG-based triage device (StrokePointer) has been developed by TrianecT with the aim to collect and analyse EEG data in patients suspected of acute stroke. In this study, we intend to validate the safety and effectiveness of the device.
HYPOTHESIS:
OBJECTIVE Primary objective is to validate the data quality and diagnostic accuracy of StrokePointer to detect LVO stroke among patients with a suspected stroke in the pre-hospital setting.
STUDY DESIGN CROSSROADS-EEG is an investigator-initiated, prospective, multi-centre cohort study.
STUDY POPULATION Adult patients with a suspected stroke, onset of symptoms (or last seen well) \<24 hours in the pre-hospital setting.
INTERVENTION A single measurement with a dry electrode headset EEG (approximately 2 minutes recording duration) will be performed in each patient. Clinical and radiological data will be collected. EEG data will be acquired with the improved TrianecT EEG device, StrokePointer.
MAIN STUDY END POINTS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Injuries or infections of the scalp in the area of the electrode headset placement.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
Diagnostic Test: Dry electrode EEG
A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. EEG data will be acquired with Strokepointer (TrianecT B.V., Utrecht, The Netherlands). StrokePointer is a portable EEG acquisition and analysis device. The device consists of three parts: (1) StrokePointer headset with dry electrodes to measure EEG data, (2) Portable StrokePointer suitcase that contains a mobile computing device (Android phone), CE-marked (IIa) EEG amplifier and storage compartments and (3) Software to acquire, analyse and upload EEG data.
Data quality of StrokePointer
Proportion of patients with a technically successful EEG dataset: at least 20 seconds of usable EEG (at least 3 electrodes with good skin-electrode quality on either side, no movement artifacts, no muscle artifacts) within a measurement time of 3 minutes.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Diagnostic accuracy of StrokePointer for LVO stroke
Diagnostic accuracy of StrokePointer for LVO stroke among patients with a suspected stroke, as measured with Area under the curve (AUC) as well as sensitivity and specificity
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Predictive value of StrokePointer in identifying LVO stroke
Positive and negative predictive value of StrokePointer in identifying LVO stroke
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
User friendliness
User-friendliness rating of StrokePointer by ambulance personnel and researchers: (1) after the training 80% of the users should be able to start StrokePointer and start measuring EEG-data within 120s. (2) Interviewed users score (a) usability of StrokePointer hardware on average as "makkelijk" (easy) or better, (b) StrokePointer software on average as "duidelijk" (clear) or better.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Incidence of serious adverse device-related events (Safety of StrokePointer)
Provided that the device is being used in line with the intended use, there are no occurrences of serious adverse device-related events in the study.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Incidence of skin reactions (Safety of StrokePointer)
Number of patients with an (allergic) skin reaction observed at the site of the electrode.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Diagnostic accuracy for identifying LVO stroke subgroups
Diagnostic accuracy for identifying LVO stroke within the following subgroups: sex (men vs. women) and age (above vs. below 60), as measured with sensitivity and specificity.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Discriminative power of StrokePointer
Discriminative power of StrokePointer for ischemic stroke vs stroke mimic as measured with Area under the curve (AUC) as well as sensitivity and specificity.
Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 17 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →